FDA Clears Blood Test to Detect Alzheimer's in Primary and Specialty Care

(MedPage Today) -- The FDA cleared the Elecsys pTau217 blood test to identify amyloid-beta pathology associated with Alzheimer's disease in people ages 55 and older with symptoms of cognitive decline, Roche announced Monday. The test, developed...

medpagetoday.com ·2h ago

FDA Clears Blood Test to Detect Alzheimer's in Primary and Specialty Care

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

FDA clears Roche and Eli Lilly's Alzheimer's blood test for primary and specialty care qz.com
Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test biopharmadive.com

Read the original at medpagetoday.com →

FDA Clears Blood Test to Detect Alzheimer's in Primary and Specialty Care

This story

More in Health & Medicine

ARCH and Population Health join China blitz with Haisco deal

More US employers to drop weight-loss drugs in 2027, as healthcare costs increase

FDA approves Jazz’s Ziihera for HER2+ gastric cancer treatment

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

Samaritan Health Services, MultiCare Health System merger approved by Oregon regulator

FDA crackdown intensifies, Mumbai’s famous Ayub’s latest on list